Drugs / Glecaprevir/pibrentasvir
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT05637879 Comparator | Dec 2023 → Dec 2025 overdue | post-traumatic stress disorder | White River Junction Veterans Affairs Medical Center | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Glecaprevir/pibrentasvir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05637879 ↗ |
| Known as | GLE/PIB | “Glecaprevir/pibrentasvir (GLE/PIB), a direct acting antiviral (DAA) that has been associated with posttraumatic stress disorder (PTSD) symptom improvement when prescribed for...” NCT05637879 ↗ |
| Route | Oral | “3 oral tablets once daily for 8 weeks.” NCT05637879 ↗ |